Zol446    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
274骨形成不全症3

274. 骨形成不全症 [臨床試験数:78,薬物数:87(DrugBank:19),標的遺伝子数:14,標的パスウェイ数:74
Searched query = "Osteogenesis Imperfecta"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 78 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-001666-40-GB
(EUCTR)
14/06/200513/05/2005An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EAn international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E Osteogenesis ImperfectaProduct Name: zoledronic acid
Product Code: ZOL446
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
130Hungary;United Kingdom
2EUCTR2004-001666-40-HU
(EUCTR)
01/02/200525/11/2004An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EAn international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E Osteogenesis ImperfectaProduct Name: zoledronic acid
Product Code: ZOL446
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
130Hungary;United Kingdom
3EUCTR2004-001666-40-BE
(EUCTR)
05/09/2005An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EAn international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E Osteogenesis ImperfectaProduct Name: zoledronic acid
Product Code: ZOL446
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
130Phase 2Hungary;Belgium;United Kingdom